Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call
Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline